LATISSE Drug Patent Profile
✉ Email this page to a colleague
When do Latisse patents expire, and when can generic versions of Latisse launch?
Latisse is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Latisse
A generic version of LATISSE was approved as bimatoprost by APOTEX on December 1st, 2014.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LATISSE?
- What are the global sales for LATISSE?
- What is Average Wholesale Price for LATISSE?
Summary for LATISSE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LATISSE |
Paragraph IV (Patent) Challenges for LATISSE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| LATISSE | Topical Solution | bimatoprost | 0.03% | 022369 | 1 | 2010-05-03 |
US Patents and Regulatory Information for LATISSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | LATISSE | bimatoprost | SOLUTION/DROPS;TOPICAL | 022369-001 | Dec 24, 2008 | AT | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LATISSE
See the table below for patents covering LATISSE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 9406433 | ⤷ Start Trial | |
| South Africa | 201405053 | TOPICAL TREATMENT FOR CHEMOTHERAPY INDUCED EYELASH LOSS OR HYPOTRICHOSIS USING PROSTAMIDE F2 ALPHA AGONISTS | ⤷ Start Trial |
| Australia | 4852693 | ⤷ Start Trial | |
| Australia | 2008203212 | Method of enhancing hair growth | ⤷ Start Trial |
| European Patent Office | 0825980 | UTILISATION DE DERIVES D'ACIDE CYCLOPENTANE HEPTAN(ENE)OIQUE, 2-HETEROARYLALKENYLE EN TANT QU'AGENTS THERAPEUTIQUES POUR LE TRAITEMENT DE L'HYPERTENSION OCULAIRE (CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION) | ⤷ Start Trial |
| Japan | 2004346080 | NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVE AS MEDICINE | ⤷ Start Trial |
| China | 1522135 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LATISSE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0660716 | 90957 | Luxembourg | ⤷ Start Trial | |
| 0660716 | SPC/GB02/035 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308 |
| 0660716 | C300099 | Netherlands | ⤷ Start Trial | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308 |
| 0660716 | SPC023/2002 | Ireland | ⤷ Start Trial | SPC023/2002: 20040929, EXPIRES: 20170307 |
| 0660716 | CA 2002 00020 | Denmark | ⤷ Start Trial | |
| 0660716 | 02C0033 | France | ⤷ Start Trial | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch